

SUPPLEMENTARY MATERIALS

Assessing the long-term (48 weeks) effectiveness, safety, and tolerability of fremanezumab in migraine in real-life: insights from the multicenter, prospective, FRIEND3 study

Piero Barbanti^{1,2*}, Gabriella Egeo^{1*}, Stefania Proietti³, Florindo d'Onofrio⁴, Cinzia Aurilia¹, Cinzia Finocchi⁵, Laura Di Clemente⁶, Maurizio Zucco⁶, Alberto Doretti⁷, Stefano Messina⁷, Massimo Autunno⁸, Angelo Ranieri⁹, Antonio Carnevale¹⁰, Bruno Colombo¹¹, Massimo Filippi¹¹, Miriam Tasillo¹², Steno Rinalduzzi¹², Pietro Querzani¹³, Giuliano Sette¹⁴, Lorenzo Forino⁴, Francesco Zoroddu¹⁵, Micaela Robotti¹⁶, Alessandro Valenza¹⁷, Cecilia Camarda¹⁸, Laura Borrello¹⁹, Marco Aguggia²⁰, Giovanna Viticchi²¹, Carlo Tomino²², Giulia Fiorentini², Bianca Orlando¹, Stefano Bonassi²³ and Paola Torelli²⁴, for the *Italian Migraine Registry study group*.

* Piero Barbanti and Gabriella Egeo made equal contributions to this work.

¹Headache and Pain Unit, IRCCS San Raffaele, Rome, Italy.

²San Raffaele University, Rome, Italy.

³Clinical and Molecular Epidemiology, IRCCS San Raffaele, Rome, Italy; Department of Human Sciences and Quality of Life Promotion, San Raffaele University, Rome, Italy.

⁴Neurology Unit, San Giuseppe Moscati Hospital, Avellino, Italy.

⁵Neurology Unit, San Paolo Hospital, ASL 2 Savona, Italy.

⁶Headache Center, Neurology Unit, San Camillo-Forlanini Hospital, Rome, Italy.

⁷Department of Neurology-Stroke Unit, Laboratory of Neuroscience, Istituto Auxologico Italiano, IRCCS, Milano, Italy.

⁸Department of Clinical and Experimental Medicine, University of Messina, Italy.

⁹Neurology Unit and Stroke-Unit, AORN A. Cardarelli, Napoli, Italy.

¹⁰Headache Center, Neurology Unit, San Filippo Neri Hospital, Rome, Italy.

¹¹Headache Unit, Department of Neurology, Scientific Institute San Raffaele Hospital, Vita-Salute University, Milan, Italy.

¹²Stroke Unit, S. Camillo de Lellis Hospital, Rieti, Italy.

¹³Neurology Unit, S. Maria Delle Croci Hospital-AUSL Romagna, Ravenna, Italy.

¹⁴Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), "Sapienza" University of Rome, Sant'Andrea University Hospital, Rome, Italy.

¹⁵Pediatric Headache Center, Neurology Unit, University of Sassari, Italy.

¹⁶Headache Center, ASST Santi Paolo Carlo, Milan, Italy.

¹⁷Headache Center, UOC Neurology, Ospedale Belcolle, Viterbo, Italy

¹⁸Department of Biomedicine, Neurosciences, and Advanced Diagnostics, University of Palermo, Palermo, Italy

¹⁹Frosinone Hospital, Headache Center, Frosinone, Italy

²⁰Neurology and Stroke Unit, Cardinal Massaia Hospital, Asti, Italy.

²¹Neurological Clinic, Marche Polytechnic University, Ancona, Italy.

²²Scientific Direction IRCCS San Raffaele, Rome, Italy

²³Clinical and Molecular Epidemiology, IRCCS San Raffaele Roma, Italy; Department of Human Sciences and Quality of Life Promotion, San Raffaele University, Rome, Italy

²⁴Neurology Unit, Department of Medicine and Surgery, Headache Center, University of Parma, Parma, Italy

Corresponding author:

Piero Barbanti, MD, PhD,

Headache and Pain Unit, IRCCS San Raffaele,

Via della Pisana 235 - 00163 Rome, Italy.

Email: piero.barbanti@sanraffaele.it; peterbrondi@gmail.com

Phone: + 39 06 5225 4026

Supplemental Table 1: Change in monthly migraine days (MMD), monthly headache days (MHD), monthly analgesic medications (MAM), Numerical Rating Scale (NRS) score, Headache Impact Test-6 (HIT-6) score, and Migraine Disability Assessment Scale (MIDAS) score from baseline to weeks 9-12 and 21-24.

Variable	HFEM (n=49)	CM (n=81)
MMD/MHD		
<i>Baseline</i>	11.1±1.8	20.4±6.0
<i>weeks 12</i>	4.2±3.5	6.7±5.6
<i>weeks 24</i>	4.3±3.7	6.5±5.8
<i>weeks 48</i>	4.7±4.0	5.9±4.9
<i>Mean change</i>		
<i>weeks 12</i>	-6.9±3.8**	-13.7±7.1**
<i>weeks 24</i>	-6.9±4.0**	-14.0±7.3**
<i>weeks 48</i>	-6.4±4.4**	-14.5±6.9**
MAM		
<i>Baseline</i>	11.7±2.9	22.1±8.5
<i>weeks 12</i>	4.6±7.2	6.1±5.1
<i>weeks 24</i>	4.2±3.6	6.1±6.0
<i>weeks 48</i>	5.7±9.4	5.6±4.9
<i>Mean change</i>		
<i>weeks 12</i>	-7.1±7.6**	-16.0±9.2**
<i>weeks 24</i>	-7.5±4.4**	-16.4±9.1**
<i>weeks 48</i>	-6.0±9.6**	-16.5±8.9**
NRS		
<i>Baseline</i>	8.1±0.9	8.1±1.2
<i>weeks 12</i>	4.1±2.1	4.7±1.8
<i>weeks 24</i>	4.3±1.7	4.6±1.9
<i>weeks 48</i>	4.8±1.9	4.7±2.0
<i>Mean change</i>		
<i>weeks 12</i>	-4.0±2.2**	-3.4±1.9**
<i>weeks 24</i>	-3.8±2.0**	-3.5±2.0**
<i>weeks 48</i>	-3.4±2.2**	-3.4±2.2**
HIT-6		
<i>Baseline</i>	67.2±3.7	68.6±4.1
<i>weeks 12</i>	49.1±15.5	46.1±21.3
<i>weeks 24</i>	41.9±19.9	44.3±21.2
<i>weeks 48</i>	50.3±9.3	50.7±12.3
<i>Mean change</i>		
<i>weeks 12</i>	-18.1±15.5**	-22.5±21.3**
<i>weeks 24</i>	-25.3±20.1**	-24.3±21.6**
<i>weeks 48</i>	-16.9±9.2**	-17.9±11.9**
MIDAS		
<i>Baseline</i>	57.5±36.3	82.6±65.6
<i>weeks 12</i>	10.5±13.6	15.0±20.7
<i>weeks 24</i>	9.0±11.4	17.5±29.5
<i>weeks 48</i>	7.1±16.1	6.0±13.6
<i>Mean change</i>		

<i>weeks 12</i>	-46.9±36.6**	-67.6±60.1**
<i>weeks 24</i>	-47.6±34.3**	-65.4±67.1**
<i>weeks 48</i>	-50.4±35.2**	-76.6±62.7**

**p<0.001